Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data
Our study provides important insight that we analyzed RWD and evaluated comparative drug safety across all type of prostate cancer. Although we could not make a conclusion whether which is the safest ARPI, we can suggest that each ARPIs have different types of AEs hence we can use this information during choosing ARPIs for prostate cancer patients.
Authors
- Jong‐Yeup Kim (ORCID: https://orcid.org/0000-0003-1230-9307)
- Sung Ryul Shim (ORCID: https://orcid.org/0000-0003-4143-7383)
- Jae Heon Kim (ORCID: https://orcid.org/0000-0002-4490-3610)
- Benjamin Inbeh Chung (ORCID: https://orcid.org/0000-0001-9660-2732)
- Jong Soo Lee (ORCID: https://orcid.org/0000-0002-9984-1138)
- Subeen Leem
- Mingchen Song (ORCID: https://orcid.org/0000-0003-3372-1560)
Institutions
- Konyang University (KR)
- Yonsei University (KR)
- Severance Hospital (KR)
- Soonchunhyang University Hospital Seoul (KR)
- Konyang University Hospital (KR)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-10-24
- DOI
- https://doi.org/10.1371/journal.pone.0335459
- Citations
- 2
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.04